NuCana plc
Business
NuCana plc is a clinical-stage biopharmaceutical company that applies proprietary ProTide phosphoramidate chemistry to transform nucleoside analog chemotherapies into more effective, better‑tolerated anti-cancer medicines. Its main products in development include ProTide candidates NUC-7738, NUC-3373 and Acelarin, each designed to improve intracellular delivery and metabolite generation while reducing toxic byproducts. The company operates through clinical development and ProTide platform technology programs, supported by intellectual property management and third‑party manufacturing relationships. It conducts global clinical trials and plans to commercialize products primarily in the United States and Europe via a focused sales force or partners.
Summary from filing dated 2025-03-20
Financials
Latest annual snapshot (FY2025, period end 2025-12-31). Full statement history unavailable for this entity.
| Revenue | — |
| Net income | $-29.35M |
| Total assets | $29.83M |
| Total liabilities | $5.51M |
| Stockholders' equity | — |
| Operating cash flow | — |